02:24 AM EDT, 07/27/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Monday that its profit and total revenue grew year over year for the first half. Profit attributable to owners of the parent for the six months ended June 30 was $5.59 billion, compared with $5.37 billion earlier. EPS moved to $3.58 from $3.44. The drugmaker's total revenue was $30.67 billion, compared with $28.05 billion a year ago. Meanwhile, the board declared a dividend of $1.06 per share for the first half, payable Sept. 8 to shareholders on record Aug. 7. It paid $1.03 per share in the year-ago period. For the full year, AstraZeneca maintained its guidance of mid-to-high single-digit growth in total revenue, alongside a low-double-digit increase in core EPS.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.